Sign up
Log in
Why Vanda Pharmaceuticals Shares Are Trading Higher By Around 33%; Here Are 20 Stocks Moving Premarket
Share
Listen to the news

Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) rose sharply in pre-market trading after the company reported the FDA approval of BYSANTI™ (milsaperidone) for the treatment of bipolar I disorder and schizophrenia – a new chemical entity opening new horizons in psychiatric innovation.

Vanda Pharmaceuticals shares jumped 33% to $7.65 in the pre-market trading session.

Here are some other stocks moving in pre-market trading.

Gainers

  • Tian Ruixiang Holdings Ltd (NASDAQ:TIRX) gained 104.2% to $0.090 in pre-market trading after dipping 15% on Friday. TIAN RUIXIANG, last week, announced a 1-for-50 reverse share split.
  • Venhub Global Inc (NASDAQ:VHUB) gained 40.7% to $2.80 in pre-market trading after falling 33% on Friday.
  • Signing Day Sports Inc (NYSE:SGN) gained 23.1% to $0.64 in pre-market trading after adding around 25% on Friday. Signing Day Sports, last week, announced effectiveness of its Form S-4 registration statement on a business combination agreement with BlockchAIn.
  • Brand Engagement Network Inc (NASDAQ:BNAI) gained 21.8% to $23.13 in pre-market trading. Brand Engagement Network recently announced the termination of its $50 million standby equity purchase agreement with YA II PN.
  • Psyence Biomedical Ltd (NASDAQ:PBM) gained 20% to $3.00 in pre-market trading. Psyence BioMed announced exercise of put option by PsyLabs and Strategic Equity Investment.
  • Primech Holdings Ltd (NASDAQ:PMEC) rose 19.7% to $0.85 in pre-market trading after gaining 7% on Friday.
  • Kaixin Holdings (NASDAQ:KXIN) rose 14.4% to $0.63 in pre-market trading after falling over 8% on Friday.
  • Rackspace Technology, Inc. (NASDAQ:RXT) gained 11.4% to $1.87 in pre-market trading after surging 37% on Friday. The company, last week, announced a strategic partnership with data-giant Palantir Technologies, Inc. (NASDAQ:PLTR), designed to accelerate deployment of Palantir's Foundry and Artificial Intelligence Platform (AIP).
  • MoonLake Immunotherapeutics (NASDAQ:MLTX) surged 9.6% to $20.57 in pre-market trading. MoonLake reported Phase 2 S-OLARIS data showing sonelokimab achieved 80%+ ASAS40 response in axial spondyloarthritis with PET/MRI imaging confirming deep tissue inflammation reduction.

Losers

  • iPower Inc (NASDAQ:IPW) fell 16% to $2.73 in pre-market trading after the company reported second-quarter results. iPower posted a quarterly loss of $1.08 per share, versus a year-ago profit of 30 cents per share.
  • Knorex Ltd (NYSE:KNRX) dipped 14.1% to $1.40 in pre-market trading after falling 32% on Friday. KNOREX recently announced the launch of its agentic AI-ready Ads API to power cross-channel advertising automation.
  • AIOS Tech Inc (NASDAQ:AIOS) fell 13.4% to $0.53 in pre-market trading after surging 37% on Friday.
  • Ensysce Biosciences Inc (NASDAQ:ENSC) shares dipped 10.2% to $0.36 in pre-market trading.
  • Rubico Inc (NASDAQ:RUBI) fell 9.9% to $1.19 in pre-market trading after dipping 26% on Friday.
  • Blue Hat Interactv Entrtnmnt Technlgy (NASDAQ:BHAT) dipped 9.8% to $0.10 in pre-market trading. Blue Hat Interactive Entertainment Technology shares dipped around 74% on Friday after pricing a $6.4 million public offering that adds new shares and warrants.
  • SS Innovations International Inc (NASDAQ:SSII) tumbled 8.5% to $4.42 in pre-market trading after gaining 10% on Friday.
  • HomesToLife Ltd (NASDAQ:HTLM) fell 8% to $2.09 in pre-market trading after gaining 24% on Friday.
  • Novo Nordisk A/S (NYSE:NVO) declined 8% to $43.60 in pre-market trading after the company disclosed headline results from REDEFINE 4, an open-label phase 3 trial from the global REDEFINE clinical trial programme.
  • Smurfit WestRock PLC (NYSE:SW) fell 6.4% to $45.62 in pre-market trading. Smurfit WestRock recently posted downbeat quarterly results.

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.